Alpha-synuclein misfolding and aggregation are hallmarks for the progression of Parkinson’s disease. Aptamer based treatments could be well suited to the prevention of this aggregation. Aptamers are single stranded oligonucleotides which bind to a specific chemical target with high affinity and specificity. Aptamer sequences are discovered through a process known as SELEX (the systematic evolution of ligands by exponential enrichment). Here, starting pools of aptamer candidates are derived from a 2010 SELEX by Tsukakoshi et al. These pools, coupled with a novel SELEX method which employs the aggregation of alpha-synuclein, has yielded promising results towards the use of aptamers for the prevention of alpha-synuclein aggregation. Based on the combination of sequencing data, the probability of forming a G-quadruplex structure, and preliminary in vitro aggregation prevention assays, the aptamer ASYN2 has been selected as an introductory candidate for in vivo testing.